Public interest group challenges ‘unmerited’ Gilead patents

26-10-2017

Public interest group challenges ‘unmerited’ Gilead patents

Hailshadow / iStockphoto.com

Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.


LSIPR